It refers to a chemical antigen receptor, which includes an antigen alliance molecule specifically combined with C-1 lecitina (cll-1),The polymerization to the antivirus molecule includes at least one (a) variable heavy chain CDR1, which contains a series of amino groups selected from the SEC group. Ibid., Nos. 17, 51, 73 and 95； (b) a variable heavy chain CDR2, including a series of amino acids selected from the SEC group. Ibid., Nos. 18, 52, 74 and 96； (c) a variable heavy chain CDR3, which includes a series of amino acids selected from the SEC group. Ibid., Nos. 19, 53, 75 and 975； (d) variable light chain CDR1, which includes a series of amino acids selected from the SEC group. Ibid., Nos. 22, 56, 78 and 100；(e) A variable light chain CDR2 containing a series of amino acids selected from the SEC group. Ibid., Nos. 23, 57, 79 and 101； (f) variable light chain CDR3, including a series of carbamates selected from the SEC group. Ibid., pp. 24, 58, 80 and 102. It also includes at least one co drive domain and one activation domain. It also involves the treatment of leukemia, lymphoma or poliomyelitis, rheumatoid arthritis, psychosis, asthma, etc.Se refiere a receptores de antigenos quimericos que comprende una molecula de union antigeno que se une especificamente a la lecitina tipo C-1 (CLL-1), en donde la molecula de union a antigeno comprende al menos uno de: a) una CDR1 de cadena pesada variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 17, 51, 73 y 95； b) una CDR2 de cadena pesada variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 18, 52, 74 y 96； c) una CDR3 de cadena pesada variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 19, 53, 75 y 975； d) una CDR1 de cadena ligera variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 22, 56, 78 y 10
